Global protein expression market was worth $1,400.4 million in 2016
According to the study, the global protein expression market is likely to grow from $1.4 billion in 2016 to $3.0 billion by 2023. Major key players in the market are developing products with technically advanced features that are designed to produce high protein yield, maintaining a balance of speed and scalability, thereby enhancing its application in the drug development workflow.
Some of the recent advanced product launched by the major players in the market include Gibco ExpiCHO expression system, launched in 2015 by ThermFisher Scientific Inc., that offers an increase yield of over 100-fold, thereby enabling upto 3g/L of protein yield; in comparison to its previous CHO system. Therefore, technically advanced products are a major factor driving the growth of the market during the forecast period.
Insights on market segments As per the findings of the research, prokaryotic expression system occupied the largest share of the protein expression market in 2016, due to the high use of prokaryotic protein expression systems, since they are cheaper as compared to other expression systems.
Based on products and services, reagents are expected to hold the largest share of the protein expression market during the forecast period, mainly attributable to increasing protein expression research activities and the large-scale production of antibodies and vaccines.
Based on application, therapeutics held the largest share of the market in 2016, owing to the increasing prevalence of chronic diseases such as cancer and diabetes around the world, and high efficacy of protein therapeutics.
Pharmaceutical & biotechnology companies were the largest end user of the protein expression products in 2016, mainly due to the technological advancement in protein expression research and rising production of recombinant therapeutic proteins for disease treatment.
North America stands as the largest protein expression market Geographically, North America has been the largest market for protein expression, with the U.S. being the larger contributor to the regional market, as compared to Canada. The dominant position of the North American market is mainly attributable to the rise in R&D infrastructure, increased aging population, rise in healthcare expenditure and increasing prevalence of chronic diseases in the region.
Europe is the second largest market for protein expression, after North America. The Germany has been the largest contributor to the European protein expression market, followed by the U.K. and France. The growth of the European market is mainly attributable to the growing aging population, increase in infections, rising incidences of cardiovascular diseases, chronic pain, and neurological disorders and R&D infrastructure. The protein expression market is expected to witness the fastest growth in Asia-Pacific during forecast period. Rising prevalence of diseases such as cardiovascular disease and diabetes, increasing R&D spending, growing aging population and increasing per capita income are some of the driving factors boosting the Asia-Pacific market.
Mergers and acquisitions: a key trend in the market Increasing number of acquisitions is a key trend observed in the protein expression market. The key players globally are acquiring segments and/or companies to increase their share in the global market. In January 2017, Bio-Rad Laboratories, Inc. (Bio-Rad) acquired RainDance Technologies, Inc. (RainDance). As per the terms of acquisition, RainDance Technologies, Inc. offered its droplet-based solutions to Bio-Rad Laboratories, Inc. and has extended its reach into next generation sequencing applications. Similarly, Takara Bio USA Holdings, Inc. (“TBUSH”) acquired Rubicon Genomics, Inc. (Rubicon) in January 2017, the acquisition was aimed at expanding the product portfolio in next generation sequencing sample preparation. TBUSH also completed its acquisition of WaferGen Bio-systems, Inc. (WaferGen) in March 2017.
Key players in the market are launching new products to offer advanced protein expression products Key players are launching new products in the market to offer advanced protein expression products. In August 2017, Thermo Fisher Scientific Inc. launched Thermo Scientific Krios G3i which is designed to deliver innovative enhancements necessary for rapid adoption of cryo-EM. The Thermo Scientific Krios G3i can be used independently or together in a single particle analysis workflow to make structural analysis of the proteins, protein complexes and other biomolecular structures faster, easier and more accessible.
In July 2017, Agilent Technologies Inc. expanded its portfolio of instruments for molecular diagnostics with the introduction of the AriaDx Real-Time PCR System. Real-time polymerase chain reaction (PCR) is routinely used in laboratories to help identify pathogens, genotype infectious agents, and for cancer diagnostics. The open platform of AriaDx makes it compatible to existing fast chemistry-based assays that are DNA binding and probe-based. This feature enables assay developers and partners with optimized reaction chemistries to quickly validate their assays on the AriaDx.
Some of the other key players operating in this industry include Merck KGaA, Genscript Biotech Corporation, Agilent Technologies, Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., New England Biolabs Inc., and Lonza Group Ltd.
Our reports have been used by over 10K customers, including:
210 pages •
By Persistence Market Research
• Jan 2018
A comprehensive, systematically structured research report on in vitro protein expression market by Persistence Market Research enables the reader to chalk down strategies to progress with the changing pace of the global market scenario.The research report is backed up with a unique research methodology, which presents data and statistics...